Great Lakes Advisors LLC Buys 17,273 Shares of GSK PLC Sponsored ADR $GSK

Great Lakes Advisors LLC boosted its position in GSK PLC Sponsored ADR (NYSE:GSK) by 54.0% in the third quarter, HoldingsChannel.com reports. The firm owned 49,279 shares of the pharmaceutical company’s stock after acquiring an additional 17,273 shares during the period. Great Lakes Advisors LLC’s holdings in GSK were worth $2,127,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Valeo Financial Advisors LLC raised its stake in shares of GSK by 7.6% during the 3rd quarter. Valeo Financial Advisors LLC now owns 14,078 shares of the pharmaceutical company’s stock worth $608,000 after acquiring an additional 999 shares in the last quarter. FSB Premier Wealth Management Inc. purchased a new position in GSK in the third quarter worth $213,000. CNB Bank acquired a new position in shares of GSK during the third quarter worth $31,000. Root Financial Partners LLC purchased a new stake in shares of GSK during the 3rd quarter valued at $67,000. Finally, NBT Bank N A NY boosted its position in shares of GSK by 10.0% in the 3rd quarter. NBT Bank N A NY now owns 16,243 shares of the pharmaceutical company’s stock worth $701,000 after purchasing an additional 1,478 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Price Performance

Shares of GSK stock opened at $51.60 on Friday. The firm has a market cap of $105.17 billion, a PE ratio of 14.57, a P/E/G ratio of 1.49 and a beta of 0.45. GSK PLC Sponsored ADR has a twelve month low of $32.38 and a twelve month high of $51.69. The company has a quick ratio of 0.55, a current ratio of 0.84 and a debt-to-equity ratio of 0.95. The business has a 50-day moving average price of $49.01 and a 200 day moving average price of $44.26.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.22. The firm had revenue of $11.35 billion for the quarter, compared to analyst estimates of $8.21 billion. GSK had a return on equity of 48.64% and a net margin of 17.16%.The business’s revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.50 EPS. Sell-side analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on GSK. Barclays downgraded shares of GSK from an “equal weight” rating to an “underweight” rating in a report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of GSK in a research note on Friday, January 16th. HSBC reiterated a “reduce” rating on shares of GSK in a research note on Wednesday, December 10th. Jefferies Financial Group reissued a “buy” rating on shares of GSK in a research report on Monday, October 27th. Finally, Bank of America raised GSK from an “underperform” rating to a “neutral” rating in a research report on Tuesday, November 25th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and four have issued a Sell rating to the company. According to MarketBeat, GSK presently has an average rating of “Reduce” and an average target price of $44.13.

Insider Transactions at GSK

In other news, major shareholder Plc Gsk purchased 1,470,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was purchased at an average cost of $19.00 per share, for a total transaction of $27,930,000.00. Following the completion of the transaction, the insider owned 18,245,691 shares of the company’s stock, valued at $346,668,129. This trade represents a 8.76% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 10.00% of the company’s stock.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.